

208. The method according to claim 207 wherein the GDNF polypeptide produced is secreted by said host cell.

209. The method according to claim 208 further comprising a step of refolding the GDNF polypeptide produced to form a disulfide-bonded dimer.

210. The method according to claim 206 wherein said nucleic acid further comprises a codon encoding an amino-terminal methionine residue when said GDNF polypeptide is recombinantly produced by a bacterial expression system.

211. The method according to claim 210 further comprising a step of refolding said GDNF polypeptide to form a disulfide-bonded dimer.

212. The method according to claim 211 wherein said said GDNF polypeptide is recombinantly produced by a bacterial expression system in *E. coli*.

213. The method according to claim 212 wherein said GDNF polypeptide is refolded to form a disulfide-bonded dimer.

REMARKS

Claims 88-90, 94, 118-120, 124, 135, 137-140, 142, 150, 152, 154-157, 160, 165-171, and 175-177 were previously allowed. The claims that were pending in the case were either rewritten or cancelled (to remove duplicative claims) and then reordered and renumbered, at the Examiner's request to facilitate completion of the reopened examination. The amendments proposed herein are entirely formalistic in nature and are intended to place the case in suitable condition for allowance.

Basis in the Specification for Claim 178(f) can be found in Example 2. More specifically, Example 2 describes the cloning of a human polynucleotide encoding a fragment of human GDNF using a PCR product generated by the amplification of a rat cDNA library. The PCR probe was amplified using primers designed to amplify the DNA fragment encoding amino acid

2 to 86 of SEQ ID NO:4. This PCR product was then successfully used as a probe to screen for polynucleotides encoding human GDNF. Therefore, Example 2 from pg. 57, line 24 through pg. 66, line 34 provides basis for Claim 178(f).

Applicants also respectfully request consideration of the new claims presented herein and passage of the case to issue. Applicants' representative would appreciate the opportunity to talk with the Examiner, in person or by telephone, to discuss the requirement of a Terminal Disclaimer in the present case and any remaining questions in order to facilitate the allowance of the application.

Draft

Robert L. Sharp
Attorney for Applicants
Registration No: 45,609
Phone: (805) 447-5992

August 30, 2002

Please send all future correspondence to:
U.S. Patent Operations/RLS
Dept. 4300 M/S 27-4-A
AMGEN INC.
One Amgen Center Drive
Thousand Oaks, California 91320-1799